Latest stories on OMER
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights
Stocktwits News58 · neutralanalyst
Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder
Seeking Alpha63 · neutralproduct/pr
Omeros Reduces Convertible Debt Through Note Repurchases
TipRanks63 · neutralgeneral
OMEROS CORP (OMER) files 8-K
SEC 8-K50 · neutralgeneral
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return
Yahoo Finance73 · bullishanalyst
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
The Motley Fool54 · neutralanalyst
Omeros: Yartemlea Faces Headwinds While We Wait On Pipeline Developments
Seeking Alpha45 · neutralproduct/pr
Omeros Announces Major Convertible Notes Repurchase Plan
TipRanks71 · bullishgeneral
OMEROS CORP (OMER) files 8-K
SEC 8-K50 · neutralgeneral
Omeros Faces European Regulatory Setback Despite U.S. Approval: What’s Next for Narsoplimab’s Global Reach?
MarketChameleon34 · bearishgeneral
Why Is OMER Stock Falling Today?
Stocktwits News34 · bearishproduct/pr
OMEROS CORP (OMER) files 8-K
SEC 8-K50 · neutralgeneral
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
The Motley Fool56 · neutralanalyst
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
The Motley Fool56 · neutralanalyst
OMEROS CORP (OMER) files 8-K
SEC 8-K50 · neutralgeneral
Omeros Announces Webcast Details for Annual Meeting of Shareholders | OMER Stock News
StockTitan50 · neutralgeneral
Omeros: Launch Traction Encouraging, But Risk/Reward Looks Balanced (Initiating Hold)
Seeking Alpha50 · neutralanalyst
Omeros (OMER) Q1 2026 Earnings Transcript
Yahoo Top50 · neutralearnings
Omeros Corporation Reports First Quarter 2026 Financial Results
Morningstar50 · neutralearnings
Omeros Non-GAAP EPS of -$0.24 beats by $0.15, revenue of $9.89M beats by $5.78M
Seeking Alpha63 · neutralearnings